Hanmi Pharmaceutical has begun to conduct the insulin,optimized to administer once a week, for the first time in the world
The global Phase 1 clinical trial for the new long-acting basal insulin optimized forpatients to administer once a week has begun.
Hanmi Pharmaceutical (CEO Kwan-soon Lee)recently announced to precedethe Phase 1 clinical trial for LAPSInsulin115 in the U.S., targeting 96patients withtype 1 and 2...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
